Cargando…
Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/ https://www.ncbi.nlm.nih.gov/pubmed/22219629 |
_version_ | 1782220046390525952 |
---|---|
author | Rusovici, Raluca Sakhalkar, Monali Chalam, Kakarla V. |
author_facet | Rusovici, Raluca Sakhalkar, Monali Chalam, Kakarla V. |
author_sort | Rusovici, Raluca |
collection | PubMed |
description | PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and ameliorates neovascularization after intracameral administration. However, the safety of intracameral administration of Bevacizumab and dose–dependent toxicity on corneal endothelial cells has not been established. METHODS: Bovine corneal endothelial (BCE) cells were treated with VEGF (50 ng/ml) and/or Bevacizumab (0.1–2 mg/ml) for 72 h. Cell proliferation was measured with the water soluble tetrazolium salts (WST-1) assay. Morphological changes were recorded by bright-field microscopy of cells. Cytotoxicity in response to Bevacizumab was evaluated by trypan blue exclusion, as well as annexin V/propidium iodide (PI) staining. RESULTS: Bevacizumab was not cytotoxic at the concentrations tested and the percentage of Bevacizumab-treated cells staining positively for both PI and Annexin V was less than 1%. The anti-proliferative effects of Bevacizumab on BCE cells were dose-dependent; a dose of 1.5 mg/ml or 2 mg/ml produced a 33% (p=0.005) or 47% (p=0.001) decrease in cell proliferation compared to controls. Similar results were obtained in cells treated with a combination of Bevacizumab and VEGF. VEGF (50 ng/ml) had no significant effect on cell proliferation compared to controls. Morphology of cells was unchanged after treatment with Bevacizumab and/or VEGF compared to controls. CONCLUSIONS: Bevacizumab was safe and not toxic to BCE cells at concentrations commonly used in clinical practice. |
format | Online Article Text |
id | pubmed-3247162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Vision |
record_format | MEDLINE/PubMed |
spelling | pubmed-32471622012-01-04 Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells Rusovici, Raluca Sakhalkar, Monali Chalam, Kakarla V. Mol Vis Research Article PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and ameliorates neovascularization after intracameral administration. However, the safety of intracameral administration of Bevacizumab and dose–dependent toxicity on corneal endothelial cells has not been established. METHODS: Bovine corneal endothelial (BCE) cells were treated with VEGF (50 ng/ml) and/or Bevacizumab (0.1–2 mg/ml) for 72 h. Cell proliferation was measured with the water soluble tetrazolium salts (WST-1) assay. Morphological changes were recorded by bright-field microscopy of cells. Cytotoxicity in response to Bevacizumab was evaluated by trypan blue exclusion, as well as annexin V/propidium iodide (PI) staining. RESULTS: Bevacizumab was not cytotoxic at the concentrations tested and the percentage of Bevacizumab-treated cells staining positively for both PI and Annexin V was less than 1%. The anti-proliferative effects of Bevacizumab on BCE cells were dose-dependent; a dose of 1.5 mg/ml or 2 mg/ml produced a 33% (p=0.005) or 47% (p=0.001) decrease in cell proliferation compared to controls. Similar results were obtained in cells treated with a combination of Bevacizumab and VEGF. VEGF (50 ng/ml) had no significant effect on cell proliferation compared to controls. Morphology of cells was unchanged after treatment with Bevacizumab and/or VEGF compared to controls. CONCLUSIONS: Bevacizumab was safe and not toxic to BCE cells at concentrations commonly used in clinical practice. Molecular Vision 2011-12-20 /pmc/articles/PMC3247162/ /pubmed/22219629 Text en Copyright © 2011 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rusovici, Raluca Sakhalkar, Monali Chalam, Kakarla V. Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells |
title | Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells |
title_full | Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells |
title_fullStr | Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells |
title_full_unstemmed | Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells |
title_short | Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells |
title_sort | evaluation of cytotoxicity of bevacizumab on vegf-enriched corneal endothelial cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/ https://www.ncbi.nlm.nih.gov/pubmed/22219629 |
work_keys_str_mv | AT rusoviciraluca evaluationofcytotoxicityofbevacizumabonvegfenrichedcornealendothelialcells AT sakhalkarmonali evaluationofcytotoxicityofbevacizumabonvegfenrichedcornealendothelialcells AT chalamkakarlav evaluationofcytotoxicityofbevacizumabonvegfenrichedcornealendothelialcells |